Login to Your Account



Survival Data Could Threaten Avastin in Lung Cancer Market

By Donna Young


Tuesday, April 22, 2008
Analysts are predicting that Genentech Inc.'s Avastin could face stiff competition as a treatment for lung cancer from ImClone Systems Inc.'s Erbitux (Cetuximab) based on new data. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription